Jens Hillengass
Roswell Park Comprehensive Cancer Center · Roswell Park · Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jens Hillengass as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06627751 · Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRoswell Park Cancer Institute · recruiting · Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph1NCT06622005 · SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRoswell Park Cancer Institute · recruiting · Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- N/ANCT05312255 · Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple MyelomaRoswell Park Cancer Institute · recruiting · Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph2NCT04876248 · Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantRoswell Park Cancer Institute · active not recruiting · Plasma Cell Myeloma · principal investigator
- N/ANCT04530812 · Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple MyelomaRoswell Park Cancer Institute · completed · Plasma Cell Myeloma · principal investigator
- N/ANCT03793907 · Strength Training in Improving Pain and Quality of Life in Patients With Multiple MyelomaRoswell Park Cancer Institute · completed · Plasma Cell Myeloma · principal investigator
- Ph2NCT03457142 · Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to ChemotherapyRoswell Park Cancer Institute · terminated · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1NCT02334865 · SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyRoswell Park Cancer Institute · active not recruiting · Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Movement is medicine in multiple myeloma: elucidating exercise-mediated immune and metabolic biomarkers that predict treatment response in the bone marrow tumor microenvironmentR01CA304003 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2026 · $718,490 awarded in 2026Same name and institution; not confirmed by an ID
- Investigation of the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myelomaR03CA299053 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2025 · $20,613 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:33 UTC. The ranking covers the 200 most relevant of 27 PubMed records, and a shared surname and initials can bring in a namesake. All 27 on PubMed
- 227 citationsRCR 6.7
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Leukemia · 2018167 citationsRCR 5.9
- Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.Blood Cancer J · 2017130 citationsRCR 5.1
- 114 citationsRCR 3.7
- The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.Blood · 2018103 citationsRCR 3.6
- Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.Haematologica · 201294 citationsRCR 3.0
- Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.Haematologica · 201570 citationsRCR 2.4
- High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.Clin Cancer Res · 200160 citationsRCR 1.3
- Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.Br J Haematol · 201656 citationsRCR 1.8
- 55 citationsRCR 3.0